Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma

Abstract

Objective: To evaluate the difference between hepatitis B virus related hepatocellular carcinoma (HBV-HCC) and non-HBV non-HCV hepatocellular carcinoma (NBNC-HCC) patients based on clinical features and prognosis. Methods: A total of 175 patients with HCC were enrolled. Patients' characteristics were extracted from medical records. Among them, 107 patients were positive for HBsAg and negative for HCV-Ab while 68 patients were negative for HBsAg and HCV-Ab. Results: The patients in the NBNC-HCC group were significantly older than those in the HBV-HCC group (P = 0.045). Moreover, vascular invasion was found in 23.4% of HBV-HCC patients, which was significantly higher than that in the NBNC-HCC patients with 10.3% (P = 0.029). Kaplan-Meier analysis revealed that HBV-HCC patients had significantly worse outcomes in terms of overall survival (P = 0.036). Compared with the NBNC-HCC patients, the HBV-HCC patients had a significantly worse disease-free survival (P = 0.0018). The multivariate analysis results indicated that TNM stage (HR = 1.541, 95%CI 1.072-2.412, P = 0.002) and HBV infection (HR = 1.087, 95%CI 1.012-1.655, P = 0.042) were independent risk variables for overall survival. While vascular invasion (HR = 1.562, 95%CI 1.013-2.815, P = 0.042) and HBV infection (HR = 1.650, 95%CI 1.017-2.676, P = 0.037) were independent risk factors associated with disease-free survival. Conclusion: Our data revealed that HBV-HCC is more common in young males with vascular invasion, while NBNC-HCC occurs mostly in elderly patients, and overall survival rate is significantly better than that of HBV-HCC. Our study therefore provides evidence that patients with HBV-HCC require closer follow-up due to their poor prognosis.

Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study

“…The patients with HBV-HCC were younger, less frequently had T2DM or hypertension, had a lower BMI, and were more likely to have liver cirrhosis, capsule invasion, and vascular invasion. The results of a Japanese study support our findings ( 48 ): Xue et al. confirmed that patients with HBV-HCC were younger and more likely to have vascular invasion compared to patients with NBNC-HCC.…”

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study

“…Patients with HBV-related HCC are defined as those who are seropositive for hepatitis B surface antigen (HBsAg), are seronegative for anti-HCV antibodies and have no history of alcoholism [ 3 ]. China's HBV-related HCC incidence and mortality rates are higher than the world average [ 4 , 5 ]. HCC associated with HBV is heterogeneous, with a wide range of clinical outcomes.…”

Fidgetin as a potential prognostic biomarker for hepatocellular carcinoma

“…However, Riordan et al [9] displayed that no significant association was detected between FIGN mRNA expression and survival of HCC patients in America. A series of outcomes comparison between HBV related HCC (HBV-HCC) and non-HBV non-HCV HCC (NBNC-HCC) revealed that HBV-HCC patients had significantly shorter OS and DSF [23][24][25]; while postoperative regular antiviral therapy could prolong survival the HCC patients with baseline higher HBV DNA titter [26]. Above evidence indicate that HBV infection is an independent risk for adverse outcome in HCC patients.…”